Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>Events>This Event
  Events - November 2013


Clinical Trials in CNS

18 Nov 2013 - 19 Nov 2013 - London, UK



Bookmark and Share


SMi is proud to present the 12th Annual...

Clinical Trials in CNS

The highly anticipated and respected 12th annual Clinical Trials in CNS Conference returns to London with a two day content packed agenda featuring new approaches taken in this field towards a number of neurodegenerative disorders, from clinical trial modelling and simulation to the role of biomarkers, the agenda presents a detailed look into many aspects of drug discovery and delivery of CNS therapeutics. This innovative conference will give delegates an opportunity to gain insights through case studies and interactive discussion into the best practices in clinical trials. 

>>>>>Event highlights include:

Learn the importance of understanding the pathophysiology and biology of disease processes with use of biomarkers and imaging techniques

Discover ways to design late stage clinical trials

Overcome challenges of delivery within the CNS

Determine the legal and ethical issues behind sham surgery

KEYNOTE SPEAKERS INCLUDE:

Larry Alphs, Therapeutic Area Leader, Johnson & Johnson

Lars Bauer, Senior Medical Director TA CNS, UCB Pharma

Tom Isaacs, Co-founder, Cure Parkinson’s Trust

Kyriacos Mitrophanous, Head of Research, Oxford Biomedica

Mathieu Albasser, Post Doctoral Researcher, Eli Lilly 

Johannes Streffer, Senior Director, Experimental Medicine Europe, Janssen Research & Development

Warren Hirst, Associate Research Fellow Neurodegeneration Research, Pfizer

Eric Karran, Director of Research, Alzheimers Research UK

PLUS AN INTERACTIVE POST-CONFERENCE WORKSHOP

20TH NOVEMBER 2013 | MARRIOTT REGENTS PARK HOTEL | LONDON, UK

Defining Clinical Relevance

Workshop Leaders: Susan Mcgoldrick, Managing Director, QCTR

Audrey Jamieson, Business Development Manager, QCTR

08.30 - 12.30

**Book by 19th July 2013 and save £300**

**Book by 31st September 2013 and save £100**

Visit our website here: http://www.smi-online.co.uk/goto/clinicaltrialscns26.asp

Alternatively, contact: Jonathan Collins on +44 (0)20 7827 6734 or email: jcollins@smi-online.co.uk

Academic & Group discounts available




Further information
Scientific News
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
One Step Closer to Precision Medicine for Chronic Lung Disease Sufferers
A study led by University of North Carolina at Chapel Hill, and National Jewish Health, has provided evidence of links between SNPs and known COPD blood protein biomarkers.
Charles River Acquires Agilux
Enhances Charles River’s early-stage capabilities in bioanalytical services.
Scientists Find Lethal Vulnerability in Treatment-Resistant Lung Cancer
The study describes how the drug Selinexor killed lung cancer cells and shrank tumors in mice when used against cancers driven by the aggressive and difficult-to-treat KRAS cancer gene.
How Baby’s Genes Influence Birth Weight And Later Life Disease
The large-scale study could help to target new ways of preventing and treating these diseases.
Genes Underlying Dogs’ Social Ability Revealed
The social ability of dogs is affected by genes that also seem to influence human behaviour, according to a new study from Linköping University in Sweden.
‘Cellbots’ Chase Down Cancer, Deliver Drugs Directly to Tumors
Programmable T cells shown to be versatile, precise, and powerful in lab studies.
Drug to Treat Alcohol Use Disorder Shows Promise Among Drinkers With High Stress
The findings suggest that potential future studies with drugs targeting vasopressin blockade should focus on populations of people with AUD who also report high levels of stress.
C Dots Show Powerful Tumor Killing Effect
Nanoparticles known as Cornell dots, or C dots, have shown great promise as a therapeutic tool in the detection and treatment of cancer.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!